These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36047201)

  • 21. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
    Kimura T; Nakamura K; Miyoshi T; Yoshida M; Akazawa K; Saito Y; Akagi S; Ohno Y; Kondo M; Miura D; Wada J; Ito H
    Int Heart J; 2019 May; 60(3):728-735. PubMed ID: 31105148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of estrogen on cardiovascular injury in ovariectomized female DahlS.Z-Lepr(fa)/Lepr(fa) rats as a new animal model of metabolic syndrome.
    Murase T; Hattori T; Ohtake M; Nakashima C; Takatsu M; Murohara T; Nagata K
    Hypertension; 2012 Mar; 59(3):694-704. PubMed ID: 22275535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
    Olgar Y; Turan B
    Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
    Tahara A
    Eur J Pharmacol; 2021 Nov; 910():174486. PubMed ID: 34487707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
    Komatsu S; Nomiyama T; Numata T; Kawanami T; Hamaguchi Y; Iwaya C; Horikawa T; Fujimura-Tanaka Y; Hamanoue N; Motonaga R; Tanabe M; Inoue R; Yanase T; Kawanami D
    Endocr J; 2020 Jan; 67(1):99-106. PubMed ID: 31776304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
    Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
    Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
    Tahara A; Takasu T
    Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome.
    Hattori T; Murase T; Takatsu M; Nagasawa K; Matsuura N; Watanabe S; Murohara T; Nagata K
    J Am Heart Assoc; 2014 Dec; 3(6):e001312. PubMed ID: 25468654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
    Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Kayama Y; Takeda N; Minamisawa S; Utsunomiya K
    Sci Rep; 2017 Sep; 7(1):11906. PubMed ID: 28928461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats.
    Masuda T; Ohara K; Vallon V; Nagata D
    Am J Physiol Renal Physiol; 2022 Sep; 323(3):F361-F369. PubMed ID: 35900341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
    Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
    Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.
    Takagi S; Li J; Takagaki Y; Kitada M; Nitta K; Takasu T; Kanasaki K; Koya D
    J Diabetes Investig; 2018 Sep; 9(5):1025-1032. PubMed ID: 29352520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.
    Kamezaki M; Kusaba T; Komaki K; Fushimura Y; Watanabe N; Ikeda K; Kitani T; Yamashita N; Uehara M; Kirita Y; Shiotsu Y; Sakai R; Fukuda T; Yamazaki M; Fukui M; Matoba S; Tamagaki K
    Sci Rep; 2018 Mar; 8(1):4029. PubMed ID: 29507299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome.
    Takatsu M; Nakashima C; Takahashi K; Murase T; Hattori T; Ito H; Murohara T; Nagata K
    Hypertension; 2013 Nov; 62(5):957-65. PubMed ID: 24041949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2018 Jan; 818():545-553. PubMed ID: 29154936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.